ipilimumab

Ligand id: 6888

Name: ipilimumab

References
1. Davis T, Keler T, Graziano R, Korman AJ. (2012)
Methods of treatement using ctla-4 antibodies.
Patent number: EP1503794. Assignee: Medarex, Inc.. Priority date: 12/04/2002. Publication date: 19/09/2012.
2. FDA. 
FDA approves nivolumab plus ipilimumab combination for intermediate or poor-risk advanced renal cell carcinoma.
Accessed on 18/04/2018. Modified on 18/04/2018. www.fda.gov, https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm604685.htm?utm_campaign=Oncology%204%2F16%2F2018&utm_medium=email&utm_source=Eloqua&elqTrackId=461a88586a9a4db284ceb54da34a6a23&elq=8b10e118e0b249beb2807c129fc264e8&elqaid=3169&elqat=1&elqCampaignId=2374
3. FDA. 
Nivolumab in combination with ipilimumab.
Accessed on 17/06/2016. Modified on 17/06/2016. US Food and Drug Administration, http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm465274.htm
4. Halk EL, Korman AJ, Lonberg N. (2001)
Human ctla-4 antibodies and their uses.
Patent number: WO2001014424. Assignee: Medarex Inc. Priority date: 24/08/1999. Publication date: 01/03/2001.
5. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowski P et al.. (2015)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.
N. Engl. J. Med., 373 (1): 23-34. [PMID:26027431]
6. Motzer RJ, Tannir NM, McDermott DF, Arén Frontera O, Melichar B, Choueiri TK, Plimack ER, Barthélémy P, Porta C, George S et al.. (2018)
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.
N. Engl. J. Med., 378 (14): 1277-1290. [PMID:29562145]
7. Postow MA, Chesney J, Pavlick AC, Robert C, Grossmann K, McDermott D, Linette GP, Meyer N, Giguere JK, Agarwala SS et al.. (2015)
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.
N. Engl. J. Med., 372 (21): 2006-17. [PMID:25891304]